Astrid Gendolla
Overview
Explore the profile of Astrid Gendolla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coppola G, Brown J, Mercadante A, Drakeley S, Sternbach N, Jenkins A, et al.
BMC Public Health
. 2025 Jan;
25(1):254.
PMID: 39838307
Background: Despite the high global prevalence, burden, and direct and indicated costs, migraines are often under-diagnosed and undertreated. Understanding the prevalence of migraine and unmet needs is crucial for improving...
2.
Gendolla A, Brown J, Mercadante A, Drakeley S, Sternbach N, Jenkins A, et al.
Cephalalgia
. 2024 Dec;
44(12):3331024241276415.
PMID: 39633516
Background: Despite the high prevalence of migraine in Europe, there is limited research on the burden among people with migraine. Methods: This cross-sectional survey used patient-reported data from the 2020...
3.
Lipton R, Gendolla A, Abraham L, Jenkins A, Telfort J, Blakeman K, et al.
Headache
. 2024 Nov;
65(1):164-179.
PMID: 39601097
Objective: This review was conducted to systematically identify evidence characterizing patients with migraine who are unsuitable for triptans. Background: Triptans are not suitable as first-line treatment for all patients with...
4.
Gaul C, Gendolla A, Holle D, Gobel H, Koch M, Baufeld C, et al.
Pain Ther
. 2024 Oct;
13(6):1659-1678.
PMID: 39432188
Introduction: To provide real-world insights into migraine patient population in Germany treated with erenumab, focusing on the prescription patterns and reasons for the initial dosage choice. Methods: SPECTRE was an...
5.
Reuter U, Heinze A, Gendolla A, Sieder C, Hentschke C
Eur J Neurol
. 2024 Aug;
31(12):e16437.
PMID: 39132915
Background And Purpose: HER-MES was the first head-to-head study of erenumab against topiramate (standard of care). This post hoc analysis of the HER-MES study evaluated the effect of erenumab versus...
6.
Scheffler A, Wenzel P, Bendig M, Gendolla A, Basten J, Kleinschnitz C, et al.
J Headache Pain
. 2024 May;
25(1):79.
PMID: 38755541
Background: Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine prophylaxis. Efficacy data are mainly from clinical trials, real-world data are hardly...
7.
Ashina M, Tepper S, Gendolla A, Sperling B, Ettrup A, Josiassen M, et al.
J Headache Pain
. 2023 Nov;
24(1):155.
PMID: 37985968
Background: Eptinezumab demonstrated efficacy in adults with migraine and prior preventive treatment failures in the placebo-controlled phase of the DELIVER clinical trial; its long-term effectiveness in this population has not...
8.
Lelleck V, Schulz F, Witt O, Kuhn G, Klein D, Gendolla A, et al.
Nutrients
. 2022 Jul;
14(14).
PMID: 35889884
Migraine is a headache disorder associated with a high socioeconomic burden. The digital therapeutic sinCephalea provides an individualized low-glycemic diet based on continuous glucose measurement and is intended to provide...
9.
Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou A, Raffaelli B, et al.
J Headache Pain
. 2022 Mar;
23(1):38.
PMID: 35305579
Background: Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available...
10.
Schroder T, Kuhn G, Kordowski A, Jahromi S, Gendolla A, Evers S, et al.
J Clin Med
. 2022 Feb;
11(4).
PMID: 35207390
Background: Migraine is a headache disorder with the highest socioeconomic burden. The aim of this study was to deliver the first proof-of-concept data of the potential role of an individual...